Editorial comment: A tale too good to be true

Urologia Internationalis

Volumn 84, Issue 4, 2010, Pages 434-435

  Dahm, Philipp ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER SURVIVAL; CLINICAL PRACTICE; DISEASE MARKER; HIGH RISK PATIENT; HUMAN; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SURVIVAL TIME; UROLOGY;

EID: 77953211546     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313364     Document Type: Note

References (6)

1. Guyatt G, et al: Users' Guide to the Medical Literature: A Manual for Evidence-Based Clinical Practice, ed 2. New York, American Medical Association, 2008.
2. Scales CD Jr, et al: Evidence-based clinical practice: a primer for urologists. J Urol 2007; 178: 775-782.
3. Dahm P, et al: Users' guide to the urological literature: how to use an article about prognosis. J Urol 2010, in press.
4. Boffetta P: Exploring a cancer biomarker: the example of C-reactive protein. J Natl Cancer Inst 2010;102:142-143.
5. Breau RH, et al: Understanding results. J Urol 2009; 181: 985-992.
6. Zhang SM, et al: C-reactive protein and risk of breast cancer. J Natl Cancer Inst 2007; 99: 890-894